JPMorgan analyst Lisa Gill views the recent pullback in shares of Teladoc Health (TDOC) as a buying opportunity. The stock's 15% selloff in the past eight trading days has been driven, at least in part, by the news around telehealth in UnitedHealthcare's (UNH) Medicare Advantage business, as well as lingering concerns related to potential competition, Gill tells investors in a research note. The analyst, however, continues to see a "significant amount of runway" in the telehealth market and believes Teladoc is "very well positioned as the only comprehensive virtual care delivery solution." She keeps an Overweight rating on the shares.

Reports Q1 revenue $646.13M, consensus $637.29M. "We are pleased to report a solid start to the year, with strength in both revenue and adjusted EBITDA in the first quarter," said Mala Murthy, acting chief executive officer and chief financial officer of Teladoc Health. "During this period of transition, our team remains laser focused on our key initiatives, which include building upon our market leadership position; driving increased product penetration through our large installed base of over 90 million virtual care members; and accelerating our bottom-line performance."

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here